Joint Pain With Crohn's Disease: Why It Happens

Joint pain is the single most common problem Crohn's disease causes outside the gut, and it is not a coincidence, a separate illness you happened to collect, or evidence that you are getting old at 28. In the Swiss national cohort, joints were the most frequently recorded category by a wide margin, ahead of mouth, eye, skin and liver involvement (Vavricka 2011). How many people it affects is genuinely contested, for reasons we go through below.

The part that matters clinically, and that almost no page explains properly, is that there is not one kind of Crohn's joint pain. There are at least three, they behave differently, and only some of them move with your bowel. That is why one person swears their knees are a reliable flare warning and another has a spotless colonoscopy and cannot grip a coffee cup. Both are describing something real. This guide separates them, explains what determines which you have, and shows what to record so that the answer becomes visible to your team instead of staying an argument.

What an extraintestinal manifestation actually is

An extraintestinal manifestation, usually shortened to EIM, is inflammation caused by inflammatory bowel disease that shows up somewhere other than the bowel. It is not a side effect of your medication, it is not an unrelated diagnosis, and it is not a complication of surgery. It is the same underlying immune process expressing itself in a different tissue.

That definition does real work, because it separates three things that get muddled constantly:

1. A true extraintestinal manifestation. Joints, eyes, skin, mouth and the bile ducts are the classic sites. These are recognised in the literature, counted in cohorts, and covered by their own European guideline (Gordon 2024). We should say plainly that we were not able to access the full text of that guideline for this article, so we cite it only for the fact that dedicated guidance exists.
2. A consequence of having the disease or treating it. Iron deficiency from blood loss, bone thinning from steroid courses, vitamin deficiencies after small bowel resection, and drug side effects all cause real symptoms outside the gut, but they are downstream problems rather than the immune process turning up in a new tissue.
3. Something that has nothing to do with it. People with Crohn's get torn menisci, frozen shoulders and rheumatoid arthritis at the same rates as everyone else, and a Crohn's label can swallow a diagnosis that needed its own treatment.

Here is what the recognised manifestations look like and, crucially, whether they tend to rise and fall with bowel activity.

Two practical consequences fall out of that table. First, a new symptom outside your gut is worth reporting even when your bowel feels fine, because several of these do not wait for a flare. Second, joints are the site people notice first and report last, usually because they assume the two are unconnected. A widely read post in r/CrohnsDisease exists for exactly that reason: someone at 30 with a lumbar spine, a knee and a thumb they had written off as exercise injuries, posting a public service announcement so other people would mention theirs (r/CrohnsDisease thread). The replies are full of people saying a version of the same thing, that the connection was never explained to them.

If you have arrived here from another symptom, this section is the shared explainer. The rest of this article is about joints specifically.

How common is joint pain in Crohn's, and why the published numbers disagree

Somewhere between roughly 10% and 35% of people with Crohn's, depending entirely on what the study counted. The spread is not sloppiness. It is a definitional split that nobody explains to patients, and understanding it tells you something useful about your own situation.

The strictest counting comes from the Oxford series that defined the modern classification. Reviewing 483 people with Crohn's, it required recorded joint swelling or effusion before classifying anyone. On that basis, type 1 arthropathy occurred in 6.0% and type 2 in 4.0%, so about 10% in total. Everyone with joint pain but no swelling was placed in a separate category called arthralgia and excluded from both types (Orchard 1998).

A meta-analysis of 71 studies pooled the prevalence of arthritis in IBD at 13% (95% CI 12 to 15), sacroiliitis at 10% (8 to 12) and ankylosing spondylitis at 3% (2 to 4), and explicitly named geographical area, care setting and differing criteria as sources of large heterogeneity (Karreman 2017).

The Swiss cohort, by contrast, recorded "arthritis" in 33% of people with Crohn's from validated physician enrolment questionnaires (Vavricka 2011). We could not reconcile 33% with the 10% from Orchard's swelling-based count or the 13% pooled figure from Karreman. The most plausible benign explanation is that a questionnaire category labelled "arthritis" captured people whom Orchard would have classified as arthralgia, but the published methods available to us do not settle it, and we are not going to pretend otherwise.

Two studies that counted joint pain rather than joint swelling land much higher. In a prospective inception cohort of 103 people with early Crohn's, almost all of them biologic-naive and with a mean disease duration of 1.3 years, 65.0% reported back pain, 50.5% reported chronic back pain and 43.7% reported arthralgia (Rios Rodriguez 2022). In an IBD outpatient clinic in Brazil, 30.5% of 118 patients had at least one inflammatory musculoskeletal manifestation (Huber 2024).

Now compare that with what the pages currently ranking for this question tell you. The headline numbers being repeated are "about 20% to 30% of people with Crohn's" and "up to 46% of those with IBD", neither of which arrives attached to a study you can check. When a figure circulates without a source, the honest move is to explain the range rather than pick a number from the middle of it.

What this means for you: if you have joint pain without swelling, you are in the largest and least studied group. You are also the group most likely to be told nothing is wrong, because the strictest definitions were built around swelling.

Which joints, and what the pattern is telling you

The distribution is not random, and it is the single most informative thing you can describe to a clinician.

Type 1, pauciarticular. Fewer than five joints, predominantly large ones: knees, ankles, wrists, elbows, hips. Often asymmetrical, often one knee or one ankle. It arrives acutely and, in Crohn's, 79% of episodes were self-limiting (Orchard 1998). It is immunogenetically similar to the wider spondyloarthritis family, carrying associations with HLA-DRB1*0103, B*35 and B*27 (Orchard 2000).

Type 2, polyarticular. Five or more joints, more symmetrical, and frequently involving the metacarpophalangeal joints, meaning the knuckles at the base of your fingers. This is the pattern behind the autocomplete searches for Crohn's joint pain "in hands" and "fingers". It persisted in 89% of Crohn's cases and carries a different genetic association again, with HLA-B*44 (Orchard 1998; Orchard 2000). Genetically distinct patterns are the strongest evidence that these are not one condition of varying severity.

Axial involvement. The sacroiliac joints, where the base of the spine meets the pelvis, and the spine itself. People describe this as low back or deep buttock pain, sometimes alternating sides, with stiffness that is worst on waking and eases once they move. It is the pattern most often mistaken for a bad mattress or a gym injury.

Enthesitis. Inflammation where a tendon or ligament attaches to bone: the Achilles insertion, the plantar fascia under the heel, the elbow. It is recognised as one of the earliest lesions in spondyloarthritis and as one of the most underestimated and obscured manifestations in IBD (Akrapovic Olic 2024). In the Brazilian ultrasound study, 42.1% had an enthesitis score above the study threshold, 35.2% had synovitis and 14.7% had tenosynovitis on ultrasound of symptomatic sites (Huber 2024). Heel pain that has been called plantar fasciitis for two years is worth mentioning to your IBD team.

Does it move with your gut? The honest answer, by type

This is the question the queue of Reddit threads keeps circling, and the answer is genuinely different depending on which pattern you have.

For type 1, mostly yes. In Crohn's, 76% of type 1 arthropathy was associated with relapsing bowel disease (Orchard 1998). That is the biological basis for people who describe a knee that swells a week before their bowel goes, and it is why some people genuinely can use joints as an early signal. It is not folklore.

For type 2, mostly no. Only 42% was associated with relapsing bowel disease in Crohn's, and 89% caused persistent symptoms (Orchard 1998). If you have widespread symmetrical joint pain that ignores your gut entirely, you are describing the pattern the literature describes.

For axial disease, largely independent. This is the pattern most likely to leave someone with a clear colonoscopy and a body that still hurts, and it is the single commonest source of the "but my gut is fine" confusion. A recurring theme in colitis and Crohn's threads is people reporting years of deep remission with joint pain that never left (r/CrohnsDisease thread).

At the level of whole cohorts, bowel activity still matters. In the Swiss cohort, active disease was independently associated with having an ongoing extraintestinal manifestation in Crohn's, with an odds ratio of 1.95 (95% CI 1.17 to 3.23), as was a positive family history of IBD, odds ratio 1.77. No such risk factors were identified in ulcerative colitis (Vavricka 2011). A later analysis of 3,298 patients from the same cohort found female sex, longer disease duration, previous IBD-related surgery, the presence of other extraintestinal manifestations, and anti-TNF treatment to be independent factors associated with the onset of arthritis or arthralgia (Hiller 2019). The anti-TNF finding needs reading carefully: people with more severe disease are the people who get anti-TNF, so this is very likely a marker of severity rather than evidence that the drug causes joint pain.

The most striking evidence that joints and bowel do not move in lockstep comes from imaging. In a population-based cohort of 110 newly diagnosed IBD patients, 17 had MRI findings indicative of axial spondyloarthritis, and only 10 of those 17 had any axial symptoms at all, meaning roughly 40% of the imaging-positive group were asymptomatic. Inflammatory MRI lesions were present in the sacroiliac joints of 26.5% and the spine of 30.3% of those imaged, and the authors found no difference between ulcerative colitis and Crohn's (Vladimirova 2025). That study was funded by the Novo Nordisk Foundation, and percentages in it are calculated on the patients who completed each assessment, so the denominators vary between 99 and 110.

The relationship also runs the other way. Ileocolonoscopy in 232 people with seronegative spondyloarthritis, none selected for bowel symptoms, found inflammatory gut lesions in 65% of those with reactive arthritis and 57% of those with ankylosing spondylitis, while 65 controls had normal guts (Mielants 1988). That is a 1988 study with the methods of its era, but it is the origin of the idea that the gut and the joints in this family of diseases are one process. A more recent line of evidence points the same way from the symptom side: in 500 people with axial spondyloarthritis on biologics, 25% met Rome IV criteria for IBS symptoms, and a meta-analysis within the same paper put IBS prevalence in spondyloarthritis at 15.4% versus controls, odds ratio 1.59 (Bernard 2024).

One older observation is worth knowing because it surfaces in conversations about surgery. Comparing 164 people with Crohn's who had an ileocaecal resection with 221 who never had surgery, new arthritic complications were significantly less common after the resection (Orchard 1999). That is a 1999 case-note review, not a trial, and it is not a reason to want surgery. It is included because it supports the mechanism: the bacteria in that part of the bowel appear to be part of the story.

Inflammatory or mechanical? Five questions that separate them

Before anything else, work out which category your pain is in, because the answer changes who should be treating it. Rheumatologists use a validated set of criteria for inflammatory back pain, developed by expert consensus and validated in a cohort of 648 patients (Sieper 2009):

1. Does it improve with exercise? (odds ratio 23.1)
2. Is there pain at night, particularly the second half of the night? (odds ratio 20.4)
3. Was the onset insidious rather than sudden? (odds ratio 12.7)
4. Did it start before age 40? (odds ratio 9.9)
5. Does it fail to improve with rest? (odds ratio 7.7)

Four out of five gave a sensitivity of 77.0% and specificity of 91.7% in the original exercise, and 79.6% and 72.4% in the validation cohort. Note what those criteria do: they invert the everyday intuition about pain. Mechanical pain gets better when you rest it and worse when you use it. Inflammatory pain gets better when you move and worse when you sit still, which is why so many people with it describe being fine by lunchtime and terrible at 6am.

For peripheral joints, the equivalent questions are whether there is visible swelling, how many minutes of morning stiffness you get, and whether the pain is symmetrical. Those three plus the joint count map directly onto the type 1 versus type 2 distinction.

What else causes joint pain in Crohn's that is not enteropathic arthritis

Several things, and missing them is how people end up treated for the wrong problem for years.

Avascular necrosis, also called osteonecrosis. Bone tissue dies from loss of blood supply, most often in the hip, and it is strongly associated with corticosteroid exposure. In a nationwide cohort, people with IBD had a higher risk than matched controls, adjusted hazard ratio 1.42 (95% CI 1.25 to 1.62), with 0.62% newly diagnosed over a median 7.2 years. Higher cumulative steroid intake and exposure to a mean prednisolone-equivalent above 20 mg daily for more than a month carried higher risk (Moon 2025). In a case-control series of 85 IBD patients with avascular necrosis, the mean age at diagnosis was 47.5 years, it was diagnosed a median of 12.2 years after the IBD, most had multifocal involvement, and notably 10% had no corticosteroid exposure at all. A history of arthropathy was itself associated with avascular necrosis (Bakhshi 2023). New deep groin or hip pain that is worse on weight bearing deserves prompt assessment, especially after steroid courses.

Fibromyalgia. A meta-analysis of 882 studies put fibromyalgia prevalence at 19.9% in inflammatory bowel disease, against a general-population pooled estimate of 1.40% that itself carried very low certainty and extreme heterogeneity (D'Souza 2026). Treat the 19.9% as an order-of-magnitude signal rather than a precise number. This matters practically because fibromyalgia was explicitly named as the major confounder when researchers tried to build a screening questionnaire for spondyloarthritis in IBD clinics (Di Carlo 2018). Widespread pain that is not accompanied by swelling and does not improve with anti-inflammatory treatment needs a different plan, not a stronger version of the same one.

Drug-related joint pain. A case series described five people with IBD who developed new-onset or worsening arthritis or sacroiliitis promptly after starting vedolizumab, a gut-selective drug that modulates lymphocyte trafficking to the bowel. The authors concluded it did not appear effective for joint manifestations and might even induce them, while being explicit that five cases cannot establish prevalence (Varkas 2017). Steroid tapers are another common trigger for a spell of aching that is not the underlying disease. In Crohn's threads, people frequently describe joint pain that follows the infusion cycle, worst in the days before the next dose (r/CrohnsDisease thread). That timing pattern is worth writing down and showing your team, because it is a specific, checkable claim about a drug rather than a vague complaint.

A coincidental rheumatological diagnosis. Enteropathic arthritis is seronegative, meaning rheumatoid factor and anti-CCP antibodies are typically absent. The most upvoted reply on one of these threads was simply to see a rheumatologist and get the antibody panels run, on the reasoning that a seropositive result points to a separate process with its own treatment (r/CrohnsDisease thread). That is a fair summary of why the referral exists. The tests themselves are a job for a clinician to order and interpret.

Hormonal change. If your joint pain has a monthly rhythm, or has arrived alongside other changes in your late thirties or forties, that is worth raising separately. Our guide to why Crohn's gets worse around your period covers the cyclical pattern and the painkiller problem it creates.

Deconditioning after a hard year. Not glamorous, and often part of the picture. It usually coexists with one of the above rather than replacing it, and it is the part most amenable to change.

The NSAID question, and why the rule is more confident than the evidence

Almost every Crohn's patient has been told not to take ibuprofen. Almost none have been told where that rule came from or how strong it is. Here is the honest version, and none of what follows is a suggestion to start, stop or change any medicine.

The study behind the caution tested 209 people with IBD. Those with quiescent disease who took non-selective NSAIDs had clinical relapse rates of 17% to 28% within nine days, while nobody relapsed early on paracetamol, on the selective COX-2 inhibitor nimesulide, or on low-dose aspirin. The relapses came with rising faecal calprotectin, which is why the authors concluded the mechanism was dual inhibition of both COX enzymes (Takeuchi 2006). That is a real finding with a real mechanism, and it is one study of 209 people.

The wider picture is messier. A systematic review and meta-analysis of 18 publications found pooled relative risks for disease exacerbation with NSAID use of 1.42 (95% CI 0.65 to 3.09) in Crohn's and 1.52 (0.87 to 2.63) in ulcerative colitis, neither statistically significant, both with substantial heterogeneity. A sensitivity analysis restricted to studies at low risk of bias did find a significantly increased risk of Crohn's exacerbation, 1.53 (1.08 to 2.16), but not of ulcerative colitis, 0.94 (0.36 to 2.42). The authors wrote that, contrary to generally accepted belief, they did not find a consistent association (Moninuola 2018). This review was supported by a US National Institute of Diabetes and Digestive and Kidney Diseases career development award, not by industry.

The same paper contains a finding that almost nobody quotes: paracetamol was associated with a pooled relative risk of 1.56 (1.22 to 1.99) for IBD exacerbation, with no heterogeneity at all. The authors were careful, noting no consistent evidence and a need for further study, and the most likely explanation is confounding by indication, people reach for painkillers because they already feel unwell. But it sits awkwardly next to the confidence with which paracetamol is recommended as the safe alternative.

For the COX-2 inhibitors, there are actual randomised trials. In 222 people with ulcerative colitis in remission who had arthritis, arthralgia or a similar reason to want an anti-inflammatory, 14 days of celecoxib produced disease exacerbation in 3% versus 4% on placebo, and bowel-related adverse events in 11% of each group (Sandborn 2006). We could not retrieve a funding or conflict-of-interest statement for that trial from the record available to us, and it evaluated a drug marketed by a company whose employees appear among the authors, so read it with that in mind.

A Cochrane review pooled the evidence and found only two eligible randomised trials, both at low risk of bias, covering 381 patients. Etoricoxib over 12 weeks produced IBD exacerbation in 17% (14 of 82) against 19% (15 of 77) on placebo, risk ratio 0.88 (0.45 to 1.69). The celecoxib trial gave 4% (5 of 112) against 6% (7 of 110), risk ratio 0.70 (0.23 to 2.14). The reviewers graded the evidence low quality on the grounds of very sparse data, with 29 and 12 events respectively, and concluded that no definitive conclusions could be drawn (Miao 2014). That review reported no known conflicts of interest. "Low quality, no definitive conclusion" is not the same as "safe", and it is also not the same as "dangerous".

What actually treats it, and how good that evidence is

The short version: anti-TNF therapy has the best evidence for both ends of the problem, the gut-selective drugs are the weakest option when joints are the issue, and the whole evidence base is lower quality than the confidence with which it gets summarised.

An umbrella review of systematic reviews on treating extraintestinal manifestations found anti-TNF response rates of 59.1% to 61.8% for axial arthritis and 73.4% to 81.2% for peripheral arthritis. Vedolizumab showed the lowest improvement of any option for joint manifestations. Ustekinumab was effective for arthralgia and psoriatic arthritis but not for axial spondyloarthritis. The authors rated the evidence certainty as moderate to low throughout and called for better endpoint methods (Nardone 2025). That review carries extensive industry disclosures: several authors report lecture, advisory board or consulting fees from a long list of manufacturers including AbbVie, Janssen, Pfizer, Eli Lilly, Takeda and Bristol Myers Squibb, and three authors declare nothing.

A meta-analysis of 23 randomised trials covering 7,810 patients with moderate to severe Crohn's looked at extraintestinal outcomes reported inside the trials rather than in dedicated studies. During maintenance, ustekinumab was associated with a reduced risk of arthritis or arthralgia, incidence rate ratio 0.56 (0.36 to 0.86), and a reduced risk of fatigue, 0.53 (0.33 to 0.84). Weekly adalimumab was associated with an increased risk of fatigue, incidence rate ratio 2.79 (1.12 to 6.94), and adalimumab and infliximab were not associated with statistically significant benefits for most extraintestinal outcomes analysed (Lin 2026). The authors declared no commercial relationships. Those trials were not designed to answer this question, so the joint outcomes are secondary analyses of adverse-event and symptom data, but a signal pointing the wrong way deserves reporting as plainly as one pointing the right way.

For the older drugs, a systematic review of 13 studies found conventional synthetic DMARDs such as methotrexate and sulfasalazine gave modest benefit in peripheral arthritis but lacked efficacy for axial disease and for the bowel inflammation itself. JAK inhibitors showed promise across both conditions but need validation in the overlap population. Critically, IL-17 inhibitors, which work well in spondyloarthritis, are generally avoided in IBD because of the risk of intestinal flares (Khalil Jnyah 2025). The authors declare no competing interests.

That last point deserves its own paragraph, because it is the clearest demonstration that the gut and the joints do not simply answer to the same drug.

Exercise. The evidence here is from axial spondyloarthritis generally, not from IBD-associated disease specifically, so read it as indirect. A network meta-analysis of 59 randomised trials in 3,404 people with axial spondyloarthritis found Pilates produced the largest effects versus usual care on disease activity, function and pain, and Qigong was the only modality that significantly reduced both ESR and CRP. But no modality significantly improved spinal mobility, the CRP-based disease activity score, six-minute walk distance or quality of life, few active modalities differed significantly from one another, and certainty was low to moderate (Huo 2026). The honest summary is that structured movement beats doing nothing and no particular class of it has been shown to be best. If you are working out how to restart after a bad patch, our guide to exercising with Crohn's disease goes through the dose-response evidence and the specific situations that change the answer.

Should you ask for a rheumatology referral?

Very often, yes, and the strongest argument for it is how much gets missed without one.

In a Turkish IBD clinic series of 122 patients, the prevalence of spondyloarthritis was 28.7% and ankylosing spondylitis 8.2%, and 45.7% of those with spondyloarthritis had not been diagnosed before the study, despite having a history of inflammatory back pain or peripheral arthritis (Beslek 2009). The authors of the population-based MRI cohort reached the same conclusion from the imaging side, that axial spondyloarthritis is underdiagnosed in early IBD and needs multidisciplinary detection (Vladimirova 2025).

Two short screening tools exist precisely because gastroenterology clinics were not catching this.

The DETAIL questionnaire is six items covering peripheral synovitis, dactylitis (a whole swollen finger or toe), enthesitis, and inflammatory low back pain. Tested on 128 IBD patients not previously diagnosed with spondyloarthritis, 21 (16.4%) turned out to meet ASAS criteria. Three affirmative answers out of six gave a post-test probability of 75% or more. The items on dactylitis and inflammatory low back pain performed best; the item asking about duration of low back pain performed worst. Fibromyalgia was named as a major confounder (Di Carlo 2018).

The IBIS-Q is a 14-item questionnaire developed in a combined rheumatology and gastroenterology clinic. Of 181 consecutive patients, 56 met ASAS criteria for spondyloarthritis, a prevalence of 30%, including 10 new cases (5.5%) found by the process. A cut-off of three positive answers gave sensitivity of 93% and specificity of 77%, with an area under the curve of 0.88 (Variola 2020). The authors note it needs validation in wider cohorts.

You do not need to complete either questionnaire yourself. What they tell you is which questions a rheumatologist considers discriminating, which means those are the things worth having ready:

• Have you had swelling in a joint, and which?
• Have you had a whole finger or toe swell up like a sausage?
• Do you get heel pain or pain at the back of the ankle?
• Do you get low back or buttock pain with morning stiffness that eases as you move?
• Did any of it start before you were 40?
• Does it wake you in the second half of the night?

A rheumatologist would typically examine joints and entheses, consider HLA-B27 testing, consider MRI of the sacroiliac joints, and rule out other causes. In the early Crohn's inception cohort, HLA-B27 positivity was strongly associated with spondyloarthritis, odds ratio 9.02 (95% CI 2.29 to 35.55), as was higher Crohn's disease activity measured by the Harvey-Bradshaw Index, odds ratio 1.14 per point (Rios Rodriguez 2022). If a clinic letter has handed you one of those Harvey-Bradshaw numbers, our guide to interpreting the score explains what each item is actually asking, including the single point it gives for joint pain.

What to track, so the pattern becomes visible

This is the part nobody writes about, and it is the part that changes what happens in the appointment. The question your team needs answered is not "do your joints hurt", it is "do your joints move with your bowel". That is a pattern question, and patterns do not survive being recalled from memory in a ten-minute slot.

Record five things:

Add the date and value of any faecal calprotectin result, because that is the objective line your gut activity gets measured against. If your calprotectin is high while you feel fine, or normal while you feel awful, that discordance is a real and common finding rather than a mistake, and our guide to a high calprotectin with no symptoms covers what it does and does not mean.

Eight weeks of that is enough. It fits on one page, and one page is roughly what gets read. Symptom trackers for a doctor's appointment goes into which chart formats clinicians actually look at and why long exports get skipped. If you would rather this happened without a spreadsheet, Clairop logs symptoms alongside meals and medication and produces a one-page summary for an appointment; how it works shows what that page contains.

A worked example: eight weeks, two people, same complaint

Both of these are composites built from the patterns in the studies above, not real patients.

Person A logs a left knee and a right ankle. Both visibly swollen for about ten days. Morning stiffness of 15 to 40 minutes on the bad days. In the same fortnight, stool frequency went from two to six a day and there were three days with visible blood. Calprotectin, taken in week 3, comes back at 640. The joints settle over a fortnight as the bowel settles.

That chart says type 1 pattern: few joints, large, swollen, one-sided, arriving with a bowel relapse. The conversation it produces is about bowel disease control, because in the Oxford series 76% of Crohn's type 1 arthropathy occurred during relapsing disease and 79% of episodes were self-limiting (Orchard 1998).

Person B logs both wrists, several knuckles on each hand, both knees and the right shoulder. No visible swelling in most of them. Morning stiffness of 60 to 90 minutes, every day, for the whole eight weeks. Low back and buttock pain that wakes them at 4am and eases once they are up and moving. Stool frequency has been steady at two a day throughout, no blood. Calprotectin in week 2 is 40.

That chart says something different: a symmetrical, persistent, small-joint pattern plus inflammatory back pain, running while the bowel is quiet. It fits the type 2 and axial descriptions, and it is the profile the IBIS-Q and DETAIL questionnaires were built to catch. The conversation it produces is about a rheumatology referral, not about escalating gut treatment, and the inflammatory back pain answers alone tick four of the five ASAS criteria (Sieper 2009).

Same complaint at the door. Two different specialties behind it. Eight weeks of notes is what makes that visible. If it is the bowel side you are trying to pin down, how to tell if you are in a Crohn's flare covers what separates a flare from the things that mimic one.

Myths worth retiring

"Joint pain means my Crohn's is flaring." Sometimes. Type 1 arthropathy tracks bowel relapse in 76% of Crohn's cases, but type 2 does so in only 42%, and axial disease largely runs its own course (Orchard 1998). Assuming every sore joint is a flare leads to unnecessary anxiety; assuming none of them are leads to missed flares.

"If my gut is in remission, joint pain must be something else." Not true, and this is the belief that keeps people from mentioning it. The MRI cohort found roughly 40% of the imaging-positive group had no axial symptoms at all, which is the same disconnect running in the opposite direction (Vladimirova 2025).

"Normal bloods rule it out." They do not. In the Brazilian ultrasound series, plasma calprotectin correlated with faecal calprotectin but not with ultrasound findings or classification criteria (Huber 2024), and axial spondyloarthritis frequently runs with a normal CRP. Examination and imaging answer questions bloods do not.

"NSAIDs always cause flares." The rule is more confident than the evidence. The pooled relative risks in the largest meta-analysis were not statistically significant for either Crohn's or colitis, although a low risk-of-bias subset did find increased Crohn's exacerbation (Moninuola 2018), and the two randomised COX-2 trials showed no significant difference from placebo on low-quality, very sparse evidence (Miao 2014). None of that makes NSAIDs safe for you personally, and none of it is a reason to change anything without your team.

"Paracetamol is the safe alternative, full stop." It is the usual alternative, and the same meta-analysis found paracetamol associated with a pooled relative risk of 1.56 (1.22 to 1.99) for IBD exacerbation (Moninuola 2018). Confounding by indication is the most likely explanation, since people in pain are people already unwell. But the clean story usually told about paracetamol is not quite what the data say.

"A drug that treats arthritis will help my Crohn's, and vice versa." Two negative trials say otherwise. Secukinumab, effective in ankylosing spondylitis, performed worse than placebo in Crohn's with more infections (Hueber 2012), and etanercept, licensed for rheumatoid arthritis, produced response in 39% against 45% on placebo (Sandborn 2001). Running the same logic in reverse, vedolizumab showed the lowest joint improvement of any option in the umbrella review (Nardone 2025) and has been reported to coincide with new arthritis in a small case series (Varkas 2017).

"It is just wear and tear, you are getting old." Possibly, and the inflammatory back pain criteria include onset before age 40 as a positive feature precisely because this presentation skews young (Sieper 2009). Reporting it costs nothing.

"Nothing can be done for it." Some things have evidence and some do not, and "take some paracetamol" is not the whole menu. Anti-TNF therapy has the best response figures for both peripheral and axial disease (Nardone 2025), conventional DMARDs have modest peripheral evidence (Khalil Jnyah 2025), and structured exercise beats usual care on pain and function in axial disease even if no single modality wins (Huo 2026). Getting to the right specialty is most of the work.

When to see a doctor promptly

Contact a doctor promptly, meaning the same day or as an emergency, if you have:

• A single hot, swollen, red joint with fever or feeling generally unwell. Infection in a joint is a medical emergency and needs excluding urgently, particularly if you take immunosuppressive treatment.
• A red, painful, light-sensitive eye or sudden change in vision. Uveitis needs treating quickly, and it is more common in Crohn's than in colitis, reported in 11.1% versus 5.6% in a Swiss cohort analysis (Biedermann 2019).
• Sudden severe groin, hip or thigh pain, worse on weight bearing, particularly after corticosteroid courses. Avascular necrosis is diagnosed on imaging and outcomes are better when it is caught early (Bakhshi 2023).

Contact your IBD team promptly, within days rather than at your next routine appointment, if you have:

• Blood in your stool that is new or increasing
• Unexplained weight loss, fever or night sweats
• Symptoms waking you from sleep, or a clear increase in stool frequency or urgency
• New or worsening abdominal pain, especially with vomiting or a swollen abdomen
• Signs of anaemia such as breathlessness, dizziness or unusual pallor
• New mouth ulcers, a new skin lesion, or joint pain and swelling that is new or clearly worse

Worth raising at your next appointment, without panic: persistent morning stiffness, heel or Achilles pain, low back pain that behaves in the inflammatory pattern, or joint pain that has not settled after a bowel flare has. If your joint symptoms are already affecting your working week, keeping a job with Crohn's disease covers the evidence on what actually predicts problems at work, and extraintestinal manifestations feature in it. If the exhaustion is as bad as the joints, Crohn's fatigue in remission covers what is worth checking and what each result would explain.

Nothing on this page is a diagnosis or a reason to start, stop or change any treatment. Bring the pattern to your team and let them do that part. If you want help structuring the conversation, our list of questions to ask your doctor about Crohn's disease includes a section on joints, eyes, skin and liver.

The honest bottom line

Joint pain is the most common thing Crohn's does outside your gut, and it is not one condition. Type 1 arthropathy hits a few large joints, usually arrives with a bowel relapse and usually settles. Type 2 hits many joints including the hands, is more symmetrical and mostly ignores what your bowel is doing. Axial involvement of the spine and sacroiliac joints runs largely on its own timetable, is the pattern most often mistaken for a bad back, and is substantially underdiagnosed.

The published prevalence figures range from about 10% to 35% because the studies are not counting the same thing, and the gap is mostly pain without swelling. Two of the key papers do not fully add up internally, and we have flagged both rather than quote the tidier number.

The NSAID rule you have been given rests on one mechanistic study and a meta-analysis whose pooled results were not statistically significant, though a low risk-of-bias subset did find increased Crohn's exacerbation, and the same analysis found an association for paracetamol that nobody quotes. Two randomised COX-2 trials found no significant difference from placebo on low-quality evidence. That is a real conversation to have with your team, not a permission slip.

Treatment evidence is better for anti-TNF than for the gut-selective drugs, and the field contains two clear negative trials where the treated arm did worse than placebo: secukinumab in Crohn's and etanercept in Crohn's. A drug that fixes one end of this does not reliably fix the other.

What you control is the quality of the information. Which joints, swelling or no swelling, minutes of morning stiffness, what your gut was doing, and the dates of your medication. Eight weeks of that turns "my joints hurt" into a chart that points at a specialty, and getting to the right specialty is most of the battle.